Clinical Trial Update: Efficacy and Safety Study of 5 mg and 10 mg Rosuvastatin [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the efficacy and safety of rosuvastatin at 5 mg and 10 mg for dyslipidemia, sponsored by D16 Pharma & Biotec Ltd.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dyslipidemia

Drugs mentioned

• Rosuvastatin (rosuvastatin)

Snippet

Sponsor: D16 Pharma & Biotec Ltd. | Conditions: Dyslipidemia | Phase 4 | Status: UNKNOWN